Adicet Bio (ACET) 9th Annual CAR-TCR U.S. Summit summary

Key clinical and translational data

• New translational data from the phase I GLEAN trial show ADI-001's robust trafficking to tissues and complete depletion of CD19-positive B cells in lymph nodes, exceeding levels seen with autologous alpha-beta CAR T therapies.

• ADI-001 demonstrated potent ex vivo killing of B cells from patients with SLE, systemic sclerosis, rheumatoid arthritis, multiple sclerosis, and Sjögren's syndrome.

• Expansion and exposure of ADI-001 in peripheral blood surpassed benchmarks set by axi-cel, with consistent B-cell depletion across multiple dose levels.

• 23 of 24 patients in the GLEAN trial experienced undetectable CD19-positive B cell counts in blood, mirroring results from anti-CD19 autologous CAR T in SLE.

• Preclinical models confirmed rapid and sustained tissue trafficking and proliferation of gamma delta 1 T cells in target lesions.

Comparative analysis with antibody therapies

• CD20-targeting antibodies like obinutuzumab and rituximab deplete B cells in blood but fail to achieve similar depletion in tissues, limiting long-term immunosuppressant-free responses.

• ADI-001's tissue trafficking and activation led to complete depletion of CD19-positive B cells in lymph nodes, a result not matched by antibody therapies.

• PET-CT imaging showed complete clinical response in extranodal lesions, further supporting tissue-level efficacy.

• Third-party publications reinforce the unique tissue trafficking advantage of gamma delta 1 T cells.

Key presentations and announcements

• Highlighted leadership in developing allogeneic gamma delta CAR T cell therapies for autoimmune diseases and cancer, with a focus on ADI-001 and ADI-270 programs.

• Announced initiation of multiple Phase 1 clinical trials in lupus nephritis, systemic lupus erythematosus, systemic sclerosis, and ANCA-associated vasculitis in 2024, with clinical updates expected in the first half of 2025.

• IND clearance and Fast Track Designation received for both ADI-001 (autoimmune) and ADI-270 (renal cell carcinoma), with Phase 1 RCC trial starting in Q4 2024.

• Projected cash runway into the second half of 2026, with $224.1M in cash and equivalents as of June 30, 2024.

• Leadership team with extensive experience in immunotherapy, cell therapy, and regulatory affairs.